Method for preparing carfilzomib intermediate compound

A technology of carfilzomib and compounds, which is applied to the preparation of organic compounds, chemical instruments and methods, and the preparation of carbamic acid derivatives, etc., can solve the problems of low yield, high cost, and high process requirements, and achieve simple operation and good conditions Mild, easy-to-control experimental operation

Active Publication Date: 2016-02-03
SHANGHAI INST OF TECH
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] Aiming at the above-mentioned technical problems in the prior art, the invention provides a kind of preparation method of carfilzomib intermediate compound, the preparation method of described this kind of carfilzomib intermediate compound solves the preparation method in the prior art Technical problems of high method cost, high process requirements and low yield

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing carfilzomib intermediate compound
  • Method for preparing carfilzomib intermediate compound
  • Method for preparing carfilzomib intermediate compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The preparation of embodiment 1 compound IV

[0056]

[0057] In a 50mL three-necked flask equipped with a thermometer, a constant pressure titration funnel, and a glass stopper, add compound L-leucine Ⅴ (5.0g, 0.038mol), add NaOH (3.0g, 0.075mol) and 15mL of water, and vigorously Stir for 5 minutes to dissolve the material completely. Slowly add (Boc) dropwise at room temperature water bath temperature control 25~30℃ 2 O (10.8 g, 0.50 mol) in THF (5 mL) was slowly heated to 50-55°C after the dropwise addition. After 0.5h, a solution of NaOH (1.5g, 0.038mol) in water (5mL) was added to the system, and the reaction was incubated for 3h. After the reaction was complete by TLC, ethyl acetate (20mL) was added to the system. Under an ice-water bath, adjust the pH value to 2-3 with 6N dilute hydrochloric acid, filter the ethyl acetate phase, wash the water phase with ethyl acetate (20 mL), combine the ethyl acetate phases, and successively wash with saturated NaHCO 3 , ...

Embodiment 2

[0058] The preparation of embodiment 2 compound III

[0059]

[0060] In a 100mL three-neck flask equipped with a thermometer, a constant pressure dropping funnel and a drying tube, add L-Boc-leucine Ⅳ (5.0g, 0.022mol) and dichloromethane (25mL), and stir vigorously for 5min to dissolve the material completely . CDI (5.6 g, 0.035 mol) was slowly added in batches under stirring in a room temperature water bath controlled at 25-30° C., and kept for 3 h. After no raw materials were detected by TLC, N,O-dimethylhydroxylamine hydrochloride (3.4 g, 0.035 mol) was slowly added in batches at 20-25° C., and reacted for 1 h. TLC detects that the intermediate state reaction is complete, and the organic phase is washed twice with 25mL water, once with 25mL1N dilute hydrochloric acid, twice with 25mL saturated sodium bicarbonate solution, once with 50mL saturated brine, and then washed with Na 2 SO 4 After drying, the system solvent was distilled off under reduced pressure to obtain ...

Embodiment 3

[0061] The preparation of embodiment 3 compound II

[0062]

[0063] In a 250mL three-neck flask equipped with a thermometer, a constant pressure dropping funnel and nitrogen protection, add III (8.2g, 0.030mol) and 40mLTHF, and stir vigorously for 5min to dissolve the material completely. Under the condition of room temperature controlled by water bath at 20-25°C, slowly add THF solution of ethylmagnesium chloride (45mL, 0.090mol) dropwise, then maintain the temperature in the range of 25-30°C for 3-4h, TLC detection until the end of the reaction. Slowly add 100mL of 1N dilute hydrochloric acid to the system to quench the system at room temperature, and add 100mL of ethyl acetate to extract the product. The ethyl acetate phase is washed twice with 50mL of saturated sodium bicarbonate solution, and then washed with 50mL of saturated brine. 2 SO 4 After drying, the solvent in the system was evaporated under reduced pressure, and the crude product was subjected to column chr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a method for preparing a carfilzomib intermediate compound. The method comprises the following steps: taking L-leucine V as a raw material, and enabling amidation between the raw material and di-tert-butyl dicarbonate ester to produce a compound IV; enabling Weinreb amidation between the compound IV and N,O-dimethylhydroxylamine hydrochloride under the action of N,N'-carbonyldiimidazole to produce a compound III; enabling grignard reaction between the compound III and an ethyl magnesium halide solution to produce a compound II; enabling aldol reaction between the compound II and formaldehyde or paraformaldehyde to produce a carfilzomib intermediate compound I ((S)-4-(tert-butoxycarbonylamino)-2,6-dimethyl-1-hepten-3-one). The method avoids use of an expensive reagent 2-bromopropylene, adopts ethylmagnesium chloride, and conforms to the design principles of highly accessible raw materials and simple operation. The synthetic route is mild in condition, the synthetic yield in each step is excellent or favorable, and the method is suitable for industrial production.

Description

technical field [0001] The invention belongs to organic chemistry, in particular to a pharmaceutical intermediate, especially a preparation method of a carfilzomib intermediate compound. Background technique [0002] Carfilzomib (Carfilzomib) is the latest second-generation epoxy ketone proteasome inhibitor approved by the US FDA. This drug is usually used in the clinical treatment of relapsed and refractory multiple myeloma. Prior treatment with two drugs including bortezomib and immunomodulators was mandatory. As a drug for treating multiple myeloma, carfilzomib has the advantages of being safe to take and not prone to drug resistance. According to the latest clinical data, carfilzomib has a significant therapeutic effect on the treatment of relapsed and refractory multiple myeloma. [0003] Carfilzomib (Carfilzomib), the chemical name is (S)-2-((S)-2-(2-(2H-1,4-oxazin-4(3H)-yl)acetamido)-4- Phenylbutyramide)-4-methyl-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxirane-2-yl) ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07C271/18C07C269/06
Inventor 刘烽陈元鹏潘仙华王琨史尧于翠郭磊李勤勤王亚萍陈彦宇
Owner SHANGHAI INST OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap